

## **MEDIA STATEMENT**

PHILOGEN SPA ANNOUNCES THE PUBLICATION IN THE PRESTIGIOUS CHEMISTRY: A EUROPEAN JOURNAL OF A COMMUNICATION ENTITLED: "A SPECIFIC AND COVALENT JNK-1 LIGAND SELECTED FROM AN ENCODED SELF-ASSEMBLING CHEMICAL LIBRARY"

Siena, Italy, May 10<sup>th</sup> 2017. [Philogen S.p.A.](#) announced today, through its fully owned subsidiary [Philochem AG](#), the publication in the prestigious Chemistry: a European Journal of a communication entitled: "A specific and covalent JNK-1 ligand selected from an encoded self-assembling chemical library".

This study, conducted in collaboration with ETH, the Institute of Pharmaceutical Chemistry and Buchmann Institute for Life Sciences, Goethe University (Germany) and the Structural Genomics Consortium and Target Discovery Institute, University of Oxford (UK), described the identification and the characteristic of covalent binders of JNK1, a kinase containing a conserved cysteine residue close to the ATP binding site. This was allowed by selections performed against JNK1 through a DNA-encoded chemical library comprising 148'135 members.

An interesting feature of the JNK1 covalent binder relates to the fact that a stoichiometric modification of a single cysteine residue in the target protein was achieved in the presence of a >1000-fold excess of glutathione, thus mimicking the thiol-rich intracellular environment.

This article is available from <http://dx.doi.org/10.1002/chem.201701644>

For additional press release topics, visit: <http://www.philogen.com/en/news/>

### **About the Philogen group**

Philogen is a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products. Philogen's strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned, and has signed agreements with several major pharmaceutical companies. For more information, please visit [www.philogen.com](http://www.philogen.com)

---